A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group​

Historical Insights on the Psychedelic Renaissance

PT386 – Vital Psychedelic Conversations

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™...

Silo Pharma Announces Expansion of Intellectual Property Portfolio

Ehave Provides Progress Update on its HPPD Study with University of...

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday,...

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding...

The Agenda for Economic Analyses of Psychedelic-assisted Therapy

A Perspective on Providers: Scaling PAT in a Time of Therapist...

Load more